Ad-hoc | 1 February 2012 13:55
WILEX AG / Key word(s): Capital Increase
01.02.2012 13:55
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
WILEX AG successfully completes rights issue
Munich, Germany, 01 February 2012. The shareholders of WILEX AG (ISIN
DE0006614720/WL6/FSE) exercised their subscription and oversubscription
rights for all of the 3,201,928 new no-par value bearer shares for EUR 3.10
per share by the end of the subscription period on 30 January 2012. As a
result, the Executive Management Board today resolved with the approval of
the Supervisory Board to set the total volume of the rights issue at
3,201,928 new shares.
Shareholders exercised subscription rights for a total of 2,417,077 new
shares, which corresponds to a subscription ratio of more than 75%. The
Company's main shareholders - dievini Hopp BioTech holding GmbH & Co. KG,
Verwaltungsgesellschaft des Golf Club St. Leon-Rot mbH and UCB Pharma S.A.
- exercised all of their subscription rights.
A total of 784,851 shares were available under shareholders'
oversubscription rights which have been placed with full allocation to the
shareholders through the custodian banks. Approximately 68 % of the
oversubscription was assigned to shareholders within the free float.
WILEX AG plans to use the gross proceeds of approximately EUR 9.93 million
from the rights issue to finance its ongoing clinical studies and continued
growth as well as to enhance its equity position.
Following the entry of the capital increase in the Commercial Register -
which is scheduled for 3 February 2012 - the total number of WILEX shares
issued will increase to 24,814,963. The subscribed and allocated new WILEX
shares are expected to be delivered on 6 February 2012, after they have
been listed on the stock exchange in the regulated market (Prime Standard).
Trading of the new shares on the stock exchange is also scheduled to
commence on 6 February 2012. Due to the different dividend entitlement the
new shares will be traded separately with the ISIN DE000A1MMAS8 until the
planned inclusion of the new shares in the existing stock exchange listing
(after the AGM on 25 May 2012). The sole lead manager of the transaction
was Landesbank Baden-Württemberg, Stuttgart (LBBW).
---------------------------------------------------------------------------
Information and Explaination of the Issuer to this News:
About WILEX AG
WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused
on oncology, the company has a broad portfolio of near-to-market
therapeutic and diagnostic products for the targeted treatment and specific
detection of various types of cancer. The company's therapeutic product
candidates are based on antibodies and small molecules. Through its US
subsidiary WILEX Inc. in Cambridge, MA, WILEX markets a portfolio of
research use only and in vitro diagnostic tests under the brand Oncogene
Science. These diagnostic tests could be developed as companion diagnostics
in clinical trials and for therapy monitoring. The wholly owned subsidiary
Heidelberg Pharma GmbH gives WILEX access to an attractive and highly
promising antibody drug conjugate technology platform and a pre-clinical
service business. The business model of WILEX covers the entire value chain
in the oncology market and comprises research, technology, development
collaboration as well as sales and marketing. WILEX's customers and
partners include leading international pharmaceutical companies. ISIN
DE0006614720 / WKN 661472 / Symbol WL6
Contact
WILEX AG
Corporate Communications
Katja Arnold (CIRO)
Grillparzerstr. 10
81675 Munich; Germany
Tel.: +49 (0)89-41 31 38-126
Fax: +49 (0)89-41 31 38-99
E-mail: investors@wilex.com
This communication contains certain forward-looking statements, relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects',
'may', 'will' 'should' 'future', 'potential' or similar expressions or by
general discussion of strategy, plans or intentions of the Company. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial condition, performance, or achievements, or industry results, to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, prospective investors and partners are cautioned not
to place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments. Given these uncertainties, prospective investors
and partners are cautioned not to place undue reliance on such
forward-looking statements. We disclaim any obligation to update any such
forward-looking statements to reflect future events or developments.
01.02.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: WILEX AG
Grillparzerstr. 10
81675 München
Germany
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info@wilex.com
Internet: www.wilex.com
ISIN: DE0006614720
WKN: 661472
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------